About SLBT

Founded: n/a
Employees: 15
CEO: Ching-Dong Wang
WebsiteView website: www.sl-bio.com

SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company’s products include SL bio’s milk-derived exosome essence, SL bio’s tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells, gamma delta T- cells, citrus reticulata (tangerine) extract, and milk-derived exosomes. SL Science Holding Limited was formerly known as SL BIO Co., Ltd. and changed its name to SL Science Holding Limited in June 2026. The company is based in Taipei, Taiwan.

Recent SLBT News & Updates

Announcement • Aug 28

SL Science Holding Limited Highlights New FDA Drug Master File For GDT Cell-Derived Exosomes Expanding Regulatory Foundation Of Its Platform

SL Science Holding Limited highlighted the filing of a new Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA). The DMF, filed under number 044612, covers exosomes derived from Gamma Delta T (GDT) cells. It was filed by JY BioMed Co. Ltd., the intellectual property holder of the GDT platform and SL Science’s licensor. This filing marks a significant milestone, as it extends the FDA-filed manufacturing and quality documentation across two formats of the same core technology: the GDT cells themselves, and the cell-free exosomes those cells secrete. A DMF streamlines future regulatory processes by providing the FDA with confidential chemistry, manufacturing, and controls (CMC) data that can be referenced in subsequent applications. Because CMC requirements are frequently a major bottleneck in cell therapy development, having this documentation already on file is expected to significantly reduce the groundwork required for downstream programs. The cell-free exosome format also addresses a critical delivery challenge in oncology. Published preclinical research demonstrates that GDT-derived exosomes carry proteins capable of both directly triggering tumor cell death and stimulating the host's own immune system. Furthermore, independent studies indicate these exosomes can work synergistically with radiotherapy and remain active in immunosuppressive tumor environments. Crucially for SL Science's focus on brain cancer, this format offers a potential solution to a well-known biological barrier. As the Company’s leadership recently highlighted in peer-reviewed literature, the primary constraint in treating glioblastoma is successfully delivering therapies across the blood-brain barrier. Unlike larger cells, extracellular vesicles such as exosomes have been shown in independent studies to actively cross an intact blood-brain barrier, reaching the central nervous system through a receptor-mediated biological route.

Recent updates

No updates

SL Science Holding Limited Stock Price

SLBT Share Price Performance

SLBT Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

SL Science Holding Limited Key Details

About SLBT

Recent SLBT News & Updates

SL Science: A $1.15 Billion Valuation Built On Preclinical Promises

SL Science Holding Files FDA DMF Expanding Exosome Platform for Oncology Drug Delivery

SL Science Holding Limited Highlights New FDA Drug Master File For GDT Cell-Derived Exosomes Expanding Regulatory Foundation Of Its Platform

Recent updates

SL Science Holding Limited Competitors

Liquidia

Kiniksa Pharmaceuticals International

Scholar Rock Holding

Travere Therapeutics